ENRIQUE CHACON | GYNAECOLOGICAL ONCOLOGY | Best Researcher Award

Posted on by sciencefather

Mr. ENRIQUE CHACON | GYNAECOLOGICAL ONCOLOGY | Best Researcher Award

Doctor at University of Navarra, Spain

Mr. Enrique Chacon is a distinguished clinician and researcher in the field of gynecologic oncology. He currently serves as a Junior Partner at the University of Navarra, specializing in diagnostic performance and tumor markers in gynecological cancers. His research focuses on innovative approaches to the management and staging of ovarian, endometrial, and cervical cancers using advanced imaging techniques, including ultrasound and MRI, as well as molecular classification for better cancer prognosis. Mr. Chacon is involved in numerous clinical projects and research studies aimed at improving cancer diagnosis, staging, and surgical outcomes. His work is widely recognized in the gynecologic oncology community, and he has contributed to many high-impact publications, particularly in leading journals such as International Journal of Gynecological Cancer and European Journal of Obstetrics & Gynecology. As an active participant in medical education, he also directs residency training programs and serves as a course director for advanced surgical anatomy and oncology. His commitment to both research and clinical practice reflects a balanced and impactful approach to advancing gynecological oncology worldwide.

Professional Profile

Education

Mr. Enrique Chacon has an extensive educational background in medicine, specializing in obstetrics and gynecology. He pursued his PhD in diagnostic performance related to transvaginal ultrasound and tumor markers in the management of indeterminate adnexal masses at the University of Navarra, Spain, a position he has held since 2017. His academic foundation is further strengthened by his clinical education in obstetrics and gynecology, where he completed his residency at Clínica Universidad de Navarra, one of Spain’s leading institutions. Chacon’s dedication to continuous professional development is evident in his participation in various specialized training courses, including advanced surgical techniques, robotic surgery, and gynecological cancer management. His commitment to both academic and clinical excellence has led him to a distinguished career, where he has further honed his skills through international rotations and advanced courses. His educational journey is marked by his pursuit of knowledge, skills, and clinical expertise, which have directly translated into his ability to contribute meaningfully to the gynecological oncology field.

Professional Experience

Mr. Enrique Chacon has extensive professional experience in both clinical practice and research within the field of gynecologic oncology. Currently, he serves as a Junior Partner at the University of Navarra, where he specializes in the diagnostic and treatment management of gynecologic cancers. In addition, he is a Clinical Collaborator in the Department of Obstetrics and Gynecology at Clínica Universidad de Navarra, a position he has held since 2019. As a practicing physician, Mr. Chacon has gained invaluable experience in treating a wide range of gynecological cancers, including ovarian, endometrial, and cervical cancers, utilizing the latest diagnostic tools and treatment protocols. Furthermore, he is responsible for directing the residency training program in obstetrics and gynecology, a role he has undertaken since 2023, where he trains the next generation of specialists in gynecological oncology. His expertise also extends to research, where he is the Principal Investigator for the SENECA study, which focuses on molecular classification in endometrial cancer staging. With a robust background in clinical practice and research, Mr. Chacon has demonstrated his ability to bridge the gap between cutting-edge research and patient care.

Research Interests

Mr. Enrique Chacon’s primary research interests lie in the advancement of diagnostic and therapeutic strategies for gynecologic cancers, particularly focusing on the role of ultrasound, tumor markers, and molecular classification in cancer staging. He is particularly interested in the diagnostic performance of transvaginal ultrasound in identifying adnexal masses and the application of tumor markers such as CA-125 and HE-4 in improving patient outcomes. His research also explores the molecular classification of endometrial cancer, a crucial area that may influence treatment strategies and prognostic assessments. Additionally, Mr. Chacon is invested in understanding the surgical outcomes of gynecologic cancer surgeries, particularly in the context of sentinel lymph node biopsies, and the use of advanced surgical techniques in gynecological oncology. He is also interested in exploring the influence of surgical volume on cancer outcomes, an area that is increasingly important in evidence-based gynecologic oncology. Through these areas of focus, Mr. Chacon aims to improve diagnostic accuracy, treatment protocols, and patient survival rates for individuals affected by gynecologic cancers.

Research Skills

Mr. Enrique Chacon possesses advanced research skills in the field of gynecologic oncology, particularly in the use of diagnostic imaging, molecular techniques, and surgical methodologies. His expertise in ultrasound imaging for the assessment of lymph node metastasis and tumor spread is a significant strength in his research portfolio. He is also proficient in the use of molecular classification techniques to stage endometrial cancer, a cutting-edge approach in cancer diagnostics. Mr. Chacon’s research skills extend to the design and execution of clinical trials, as evidenced by his role as Principal Investigator for the SENECA study. He is skilled in the management of multicenter studies and has a deep understanding of the complexities of coordinating large-scale clinical research. In addition to his imaging and molecular research expertise, Mr. Chacon is proficient in data analysis and systematic reviews, as demonstrated by his numerous publications in high-impact journals. His ability to synthesize clinical and research data allows him to contribute significantly to the development of evidence-based practices in gynecologic oncology.

Awards and Honors

Mr. Enrique Chacon has been the recipient of numerous awards and honors in recognition of his research, clinical contributions, and academic excellence. Notably, he has received the prestigious FIS National Scholarship from the Instituto San Carlos III, which has supported his PhD studies in diagnostic performance in gynecological oncology. His efforts in advancing gynecologic oncology research have also been recognized with the Top Reviewers Award from the International Journal of Gynecological Cancer in both 2022 and 2024. His involvement as a social media ambassador at the ESGO Congress in Berlin, as well as his guest editor role in Frontiers in Oncology, reflects his growing reputation within the global gynecologic oncology community. Additionally, his participation in training and leadership positions has garnered him recognition, particularly his current role as Director of the residency training program in Obstetrics and Gynecology. These awards and recognitions underscore Mr. Chacon’s outstanding contributions to the field and his commitment to improving patient care and advancing gynecological oncology research.

Conclusion

Mr. Enrique Chacon stands out as an exemplary researcher and clinician in gynecologic oncology. His extensive experience in clinical practice, coupled with his leadership in research, positions him as a leader in the field. Mr. Chacon’s commitment to advancing gynecological oncology through his work on tumor markers, diagnostic imaging, and molecular classification has made a profound impact on patient outcomes and treatment protocols. He has consistently demonstrated his ability to bridge the gap between clinical practice and research, ensuring that his findings translate directly into better patient care. His numerous awards, honors, and academic contributions further highlight his exceptional qualifications. As a dedicated educator, researcher, and clinician, Mr. Chacon’s ongoing work will likely continue to shape the future of gynecologic oncology, improving both survival rates and quality of life for patients worldwide.

Publication Top Notes

  • SUCCOR study: an international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1…
    • Authors: L Chiva, V Zanagnolo, D Querleu, N Martin-Calvo, J Arévalo-Serrano, …
    • Journal: International Journal of Gynecological Cancer, 30(9), 1269-1277
    • Citations: 241
    • Year: 2020
  • Risk of endometrial cancer and endometrial hyperplasia with atypia in asymptomatic postmenopausal women with endometrial thickness≥ 11 mm: A systematic review and meta‐analysis
    • Authors: JL Alcázar, L Bonilla, J Marucco, AI Padilla, E Chacón, N Manzour, …
    • Journal: Journal of Clinical Ultrasound, 46(9), 565-570
    • Citations: 62
    • Year: 2018
  • SUCCOR cone study: conization before radical hysterectomy
    • Authors: E Chacon, N Manzour, V Zanagnolo, D Querleu, JM Núñez-Córdoba, …
    • Journal: International Journal of Gynecologic Cancer, 32(2)
    • Citations: 50
    • Year: 2022
  • Ovarian adnexal reporting data system (O-RADS) for classifying adnexal masses: a systematic review and meta-analysis
    • Authors: J Vara, N Manzour, E Chacon, A Lopez-Picazo, M Linares, MA Pascual, …
    • Journal: Cancers, 14(13), 3151
    • Citations: 37
    • Year: 2022
  • Oncologic outcomes of endometrial cancer in patients with low-volume metastasis in the sentinel lymph nodes: an international multi-institutional study
    • Authors: K Ghoniem, AM Larish, G Dinoi, XC Zhou, M Alhilli, S Wallace, …
    • Journal: Gynecologic Oncology, 162(3), 590-598
    • Citations: 37
    • Year: 2021
  • Risk of ovarian malignancy algorithm versus risk malignancy index-I for preoperative assessment of adnexal masses: a systematic review and meta-analysis
    • Authors: E Chacón, J Dasí, C Caballero, JL Alcázar
    • Journal: Gynecologic and Obstetric Investigation, 84(6), 591-598
    • Citations: 33
    • Year: 2019
  • Magnetic resonance imaging and ultrasound for assessing parametrial infiltration in cervical cancer. A systematic review and meta-analysis
    • Authors: JL Alcázar, E García, M Machuca, R Quintana, J Escrig, E Chacón, …
    • Journal: Medical Ultrasonography, 22(1), 85-91
    • Citations: 22
    • Year: 2020
  • SUCCOR study. An international European cohort observational study comparing minimally invasive surgery versus open abdominal radical hysterectomy in patients with stage IB1…
    • Authors: L Chiva, V Zanagnolo, A Kucukmetin, G Chakalova, F Raspagliesi, …
    • Journal: International Journal of Gynecologic Cancer, 29(Suppl 4)
    • Citations: 20
    • Year: 2019
  • Diagnostic performance of transvaginal ultrasound for detecting cervical invasion in women with endometrial carcinoma: a systematic review and meta‐analysis
    • Authors: JL Alcázar, L Perez, O Güell, N Haro, N Manzour, E Chacón, M Jurado
    • Journal: Journal of Ultrasound in Medicine, 38(1), 179-189
    • Citations: 17
    • Year: 2019
  • Prognostic value of isolated tumor cells in sentinel lymph nodes in low-risk endometrial cancer: results from an international multi-institutional study
    • Authors: G Cucinella, G Schivardi, XC Zhou, M AlHilli, S Wallace, C Wohlmuth, …
    • Journal: International Journal of Gynecologic Cancer, 34(2)
    • Citations: 12
    • Year: 2024

 

 

Joanna Jazowiecka-Rakus | oncolytic virotherapy | Best Researcher Award

Posted on by sciencefather

Joanna Jazowiecka-Rakus | oncolytic virotherapy | Best Researcher Award🏆


Assistant Professor at Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland
🎓

Joanna Jazowiecka-Rakus is an Assistant Professor with a strong focus on advancing cancer research through innovative oncolytic therapies. Her work at the Maria Skłodowska Memorial National Institute of Oncology in Gliwice, Poland, positions her as a leading expert in experimental cancer treatments. Dr. Jazowiecka-Rakus’s pioneering research in oncolytic virotherapy and nanocarrier drug delivery aims to address complex cancers like pancreatic adenocarcinoma, glioma, and melanoma. With a reputation for pushing boundaries in cancer treatment, she continues to make strides in developing therapies that offer new hope for patients with challenging diagnoses.

Professional Profile 

🎓 Education

Dr. Jazowiecka-Rakus holds a Master of Science in Biology from the Faculty of Biology, University of Silesia, Katowice, Poland (2001), followed by a Ph.D. in Medical Biology from the National Institute of Oncology, Warsaw, Poland (2007). In recognition of her exceptional contributions to cancer research, she earned a D.Sc. (habilitation) in Medical Sciences from the same institution. Her academic path reflects her dedication to enhancing cancer treatment through rigorous scientific training and specialization.

🏢 Work Experience

Throughout her career, Dr. Jazowiecka-Rakus has held esteemed research positions, including her current role as an Assistant Professor at the National Institute of Oncology. Her work has been instrumental in projects funded by prestigious institutions like the International Center for Genetic Engineering and Biotechnology and the National Science Center of Poland. Notably, her research covers a wide spectrum of experimental cancer therapies, including the use of myxoma viruses and mesenchymal stem cells to treat melanoma, ovarian cancer, and glioma. She has also forged valuable collaborations with global institutions, such as the Biodesign Institute at the University of Arizona, Tempe, USA.

🧬 Skills

Dr. Jazowiecka-Rakus brings a wealth of expertise in cancer treatment, highlighted by her skills in oncolytic virotherapy, cancer immunotherapy, and advanced drug delivery systems. Her work with oncolytic virotherapy focuses on developing viral therapies that specifically target and destroy cancer cells, offering a promising alternative to traditional cancer treatments. In cancer immunotherapy, she integrates immune-enhancing agents to create therapies for advanced cancers. Her pioneering methods for stem cell-based drug delivery use mesenchymal stem cells as carriers for oncolytic viruses, targeting tumor cells more effectively. Additionally, she has developed nanocarrier drug formulations that improve the delivery and efficacy of drugs in cancer treatment.

Awards and Honors 🏆

Dr. Jazowiecka-Rakus’s dedication to cancer research has earned her numerous accolades. Between 2017 and 2020, she was awarded a research grant by the International Center for Genetic Engineering and Biotechnology to study oncolytic melanoma therapy, underlining her impact in this vital area. Her scholarly contributions include 18 articles published in high-impact journals indexed in Web of Science and Scopus, reflecting her influence and recognition within the cancer research community. Her works have accumulated a citation index of over 431, showcasing the significant reach and impact of her research.

🌐 Memberships

Active in professional societies, Dr. Jazowiecka-Rakus is an auditor for the Association for the Support of Cancer Research in Gliwice, Poland, where she contributes to promoting research integrity and supporting advancements in cancer studies. She is also a member of the Polish Radiation Research Society based in Warsaw, where she engages with other professionals dedicated to improving cancer treatment and sharing knowledge within the field.

📚 Teaching Experience

As an Assistant Professor, Dr. Jazowiecka-Rakus is committed to educating and mentoring the next generation of cancer researchers at the National Institute of Oncology. Her teaching covers essential aspects of oncology and medical biology, with a particular focus on innovative treatment strategies in cancer research. Through her courses and mentoring, she guides students in understanding the complexities of cancer treatment, encouraging them to pursue research that makes a real-world impact.

🔬 Research Focus

Dr. Jazowiecka-Rakus’s research centers on developing experimental therapies for aggressive cancers. Her work includes the creation of oncolytic myxoma virus constructs, which use mesenchymal stem cells as carriers to deliver viral therapies specifically targeting cancers such as pancreatic adenocarcinoma and glioma. She has developed advanced blood-brain barrier crossing techniques to treat glioma through intra-arterial delivery, offering a new method to target brain tumors effectively. Additionally, her research on 3D models for cancer uses spheroid and organoid models to test therapies for disseminated ovarian cancer, pushing the boundaries of cancer treatment with innovative laboratory models that mimic real-world conditions. Dr. Jazowiecka-Rakus’s interdisciplinary approach highlights her dedication to advancing the field of cancer therapy and improving patient outcomes.

Conclusion 

In conclusion, Dr. Joanna Jazowiecka-Rakus exemplifies the qualities of an outstanding researcher through her innovative projects, significant contributions to cancer research, and a strong academic foundation. Her ongoing work and potential for future advancements make her a deserving candidate for the Best Researcher Award. Enhancing her publication record and pursuing patent opportunities would further solidify her standing as a leader in the field.

📚 Publilcation 

  • Adipose-Derived Stem Cells as Carrier of Pro-Apoptotic Oncolytic Myxoma Virus: To Cross the Blood–Brain Barrier and Treat Murine Glioma
  • Combination of LIGHT (TNFSF14)-Armed Myxoma Virus Pre-Loaded into ADSCs and Gemcitabine in the Treatment of Experimental Orthotopic Murine Pancreatic Adenocarcinoma
  • Myxoma Virus Expressing LIGHT (TNFSF14) Pre-Loaded into Adipose-Derived Mesenchymal Stem Cells Is Effective Treatment for Murine Pancreatic Adenocarcinoma
  • Removal of Heavy Metal Ions from Wastewaters: An Application of Sodium Trithiocarbonate and Wastewater Toxicity Assessment
  • COVID-19 Autopsies: A Case Series from Poland
  • Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma
  • Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses

 

Dr Alexander Chernov| neuro-oncology | Best Researcher Award

Posted on by sciencefather

Dr Alexander Chernov| neuro-oncology | Best Researcher Award 🏆


DR at Institute of Experimental Medicine🎓

Dr. Alexander Nikolaevich Chernov is a PhD and Senior Researcher at the World-Class Research Centre “Center for Personalized Medicine” at the Institute of Experimental Medicine, Saint Petersburg, Russia 🧬. With an impressive portfolio of over 80 scientific papers, six patents, and ongoing collaborations with international institutions, Dr. Chernov has made significant contributions in the fields of neuroimmunooncology, glioblastoma research, and the study of nerve growth factors. In 2021, he defended his PhD thesis on the effects of nerve growth factor and immune peptides on brain tumor cells, and in 2022-2023, he completed a postdoctoral fellowship at Ben-Gurion University, Israel 🇮🇱.

 

Professional Profile 

Education 🎓

Dr. Chernov holds a PhD with expertise in neurobiology, focusing on brain tumors and chemotherapy. He has a solid foundation in biochemistry, serving as an assistant professor at Saint Petersburg State Pediatric Medical University 🎓.

Work Experience 🏢

Dr. Chernov’s extensive research includes working as a senior researcher at multiple prestigious institutions in Russia, including the D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology. He has also been involved in numerous consultancy and industry projects across nine different sectors.

Awards and Honors 🏆

Dr. Chernov has earned recognition for his exceptional work in brain tumor research, including the nomination for the Best Researcher Award for his article on glioblastoma sensitivity to antimicrobial peptides.

👨‍🏫 Teaching & Memberships🌍

Dr. Chernov is a dedicated educator, currently teaching biochemistry at Saint Petersburg State Pediatric Medical University. He is a member of the Belarusian Society of Physiologists, contributing to his international scientific community .

Research Focus 🔍

His main research areas include glioblastoma, nerve growth factors, chemotherapy, and antimicrobial peptides such as LL-37 and PG-1 🧠. Dr. Chernov’s groundbreaking work has shown how these peptides, in combination with chemotherapy drugs, can predict overall survival in patients with glioblastoma. His research has also demonstrated the effects of these combinations on the inhibition of glioma cell clonogenicity and migration.

Publications : 

 

  • “Cytotoxic effects of chemotherapeutic drugs and heterocyclic compounds at application on the cells of primary culture of neuroepithelium tumors”
    • Medicinal Chemistry, 2012
  • “Fourth generation phosphorus-containing dendrimers: prospective drug and gene delivery carrier”
    • Pharmaceutics, 2011
  • “Biological activity of silver-doped DLC films”
    • Diamond and Related Materials, 2009
  • “Analysis of the Spectrum of ACE2 Variation Suggests a Possible Influence of Rare and Common Variants on Susceptibility to COVID-19 and Severity of Outcome”
    • Frontiers in Genetics, 2020
  • “Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients”
    • Frontiers in Immunology, 2021
  • “The phenomenon of multidrug resistance in glioblastomas”
    • Hematology/Oncology and Stem Cell Therapy, 2021
  • “Genetic risk factors for the development of COVID-19 coronavirus infection”
    • Russian Journal of Genetics, 2021
  • “Pharmacogenetic Study of the Impact of ABCB1 Single Nucleotide Polymorphisms on the Response to Cyclosporine in Psoriasis Patients”
    • Pharmaceutics, 2022
  • “Pathophysiological mechanisms of autism in children”
    • Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova, 2020
  • “Anticancer Effect of Cathelicidin LL-37, Protegrin PG-1, Nerve Growth Factor NGF, and Temozolomide: Impact on the Mitochondrial Metabolism, Clonogenic Potential, and Migration”
    • Molecules, 2022